Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding Memorandum of Understanding (MOU) with a Vietnam-based pharmaceutical distribution company to explore the development and commercialization of MCS-2 in the Vietnamese pharmaceutical market [1][2]. Group 1: MOU Details - The MOU outlines that both parties will conduct due diligence and discussions to define the scope and structure of any potential collaboration, including commercial strategy, regulatory pathway, and local market execution [2]. - There is no guarantee that a definitive agreement will be reached or that the collaboration will be finalized [2]. Group 2: Strategic Importance - The CEO of Jyong Biotech emphasized that this MOU is a significant step in the company's Asia-focused strategy to introduce plant-derived MCS therapies to new markets, highlighting Vietnam's potential for patient access and local partnerships [3]. - This MOU follows a previously announced non-binding Letter of Intent with a South Korean pharmaceutical company to explore in-licensing and development opportunities for plant-derived MCS products [3]. Group 3: Product Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [4]. Group 4: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, with initial market focus on the U.S., EU, and Asia [5]. - Since its establishment in 2002, the company has developed integrated capabilities across all key drug development functions, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [5].

Core Viewpoint - Jyong Biotech Ltd. has entered into a non-binding letter of intent with a South Korean pharmaceutical company to explore the potential in-licensing and development of its plant-derived new drug MCS-2 for the Korean market [1][2] Group 1: Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][4] - The company has been operational since 2002 and has developed integrated capabilities across drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - Jyong Biotech is advancing several botanical drug candidates, including its primary candidate BOTRESO® and other clinical and preclinical-stage candidates [4] Group 2: Strategic Partnership - The engagement with the South Korean pharmaceutical company aligns with Jyong Biotech's co-commercialization strategy, aiming to leverage the partner's established sales networks and local regulatory expertise [2] - The partnership, if finalized, is expected to enhance market access and patient reach in Korea by utilizing the partner's commercial infrastructure [2][3] - The letter of intent is non-exclusive and subject to due diligence, regulatory review, and negotiation of definitive agreements [2] Group 3: Product Development Status - MCS-2 is currently an investigational new drug candidate and has not yet received approval for commercial use in any jurisdiction [3] - The company is committed to complying with regulatory disclosure obligations and will provide updates on material developments as they occur [3]

Core Insights - Jyong Biotech Ltd. has been awarded the Innovation Gold Award for its oral plant-derived investigational new drug BOTRESO® at the 2025 Taipei Biotech Awards, highlighting its commitment to innovation in the biotechnology sector [1][3][4] Company Overview - Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases, targeting markets in the U.S., EU, and Asia [1][5] - The company has established integrated capabilities across all key drug development functions, including drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization since its inception in 2002 [5][6] Product Development - BOTRESO® is recognized as the first Taiwan-developed oral botanical new drug to receive U.S. FDA Investigational New Drug (IND) approval and has completed four Phase III clinical trials [2][3] - The product holds multiple invention patents for its pharmaceutical composition globally and has a New Drug Application (NDA) submitted to the U.S. FDA [2][3] Recognition and Future Plans - The award received by the company underscores its leadership in plant-derived drug innovation and its ongoing commitment to delivering effective therapies to patients worldwide [4] - The company aims to expand its global presence and continue developing first-class botanical new drugs to address critical healthcare needs [4]

Core Insights - Jyong Biotech Ltd. has completed patient enrollment in its Phase II clinical trial for MCS-8, an investigational drug candidate aimed at prostate cancer prevention, with over 700 high-risk subjects enrolled [1][3] - The trial is randomized and placebo-controlled, taking place across 20 hospitals in Taiwan with the involvement of more than 130 urologists [2] - The company has expressed satisfaction with reaching this milestone, highlighting the team's professionalism and dedication despite challenges posed by the COVID-19 pandemic [3] Company Overview - Jyong Biotech Ltd. is a science-driven biotechnology company based in Taiwan, focusing on developing and commercializing innovative plant-derived drugs, particularly for urinary system diseases [4] - Established in 2002, the company has developed integrated capabilities across all key drug development functions, including discovery, clinical trials, regulatory affairs, manufacturing, and commercialization [4] - The company aims to provide first-class innovative drugs to meet health needs and aspires to be a respected organization in the industry [4]